Jaguar Health Reports 2022 Financial Results - Prescription Revenues ...
Jaguar Health Reports 2022 Financial Results - Prescription Revenues ...
Source: pr-inside.com
📰 Ontarget Phase News
Ontarget Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ontarget Phase. Real-time updates on events, politics, business and more.
Jaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021Core initiatives:OnTarget
Source: finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted cancer therapySAN
Source: finanznachrichten.de
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
Jaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2022 First Quarter Financials
Mytesi® net revenue of $2.6 million increased approximately 24% over the fourth quarter of 2021 and increased approximately 112% over Mytesi net revenue in the first quarter of 2021Core initiatives:OnTarget
Source: finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
Click here to access webcast replayCore 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation
Peter Hodge Napo Pharmaceuticals Jaguar Health Jaguar Animal Health Jaguar Health Inc Napo Pharmaceuticals Inc
Source: finanznachrichten.de
Jaguar Health, Inc.: Jaguar Health Provides Company Updates and Reports 2021 Financials
Core 2022 development initiatives:Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD)Initiation and completion in 2H 2022
Source: finanznachrichten.de
Jaguar Health Provides Company Updates and Reports 2021 Financials
Press release content from Accesswire. The AP news staff was not involved in its creation.
Source: apnews.com
Jaguar Health, Inc.: Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure
Source: finanznachrichten.de